Zelenectide Pevedotin
InvestigationalAlso known as: BT8009, Bicycle Drug Conjugate BT8009
A first-in-class Bicycle Drug Conjugate (BDC) targeting Nectin-4 for solid tumors, developed by Bicycle Therapeutics. Demonstrates 45% overall response rate in metastatic urothelial cancer with a novel bicyclic peptide platform approximately 40x smaller than traditional antibody-drug conjugates. Phase 2/3 Duravelo-2 registrational trial ongoing.
Research Statistics
Bicyclic peptide-drug conjugate (BT5528/BC-CRX-001) targeting EphA2 in Phase 1 oncology trials. US and international trial sites. EphA2-targeted delivery mechanism is well-reasoned based on established ADC biology; limited efficacy data at early Phase 1 stage.
Research Dossier
Overview
What is Zelenectide Pevedotin and what does the research say?
Mechanism of Action
The mechanism of zelenectide pevedotin is well-characterized through extensive preclinical and clinical research. Human clinical data supports the proposed mechanism.
How It Works (Simplified)
Zelenectide pevedotin functions as a precision “smart missile” targeting cancer cells:
Bicyclic peptide binds Nectin-4 protein overexpressed on cancer cells (60-90% in urothelial cancer) with sub-nanomolar affinity.
Small size (~2-3 kDa vs ~150 kDa for ADCs) enables fast, deep tumor penetration within hours rather than days.
After internalization, lysosomal enzymes cleave the linker releasing MMAE cytotoxin inside the cancer cell.
MMAE blocks tubulin polymerization, arrests mitosis, and triggers apoptosis. Bystander effect kills neighboring tumor cells.
Scientific Pathways
Nectin-4 Targeting and Internalization (Primary Mechanism)
Zelenectide pevedotin (IV) → Rapid tumor distribution (small size)
↓
Bicyclic peptide binds Nectin-4 (sub-nM affinity)
↓
Receptor-mediated endocytosis → Lysosomal traffickingMMAE Release and Cytotoxicity (Payload Mechanism)
Cathepsin B cleaves valine-citrulline linker → Free MMAE released
↓
MMAE binds tubulin → Blocks polymerization
↓
Mitotic arrest → Apoptosis (cell death)Key Research: Bennett G et al. (2020) demonstrated superior tumor penetration of Bicycle platform vs ADCs. PMID:32241873
Important Limitations
- Investigational drug not yet approved by FDA or other regulatory agencies
- Available only through clinical trial enrollment (NCT04561362, NCT05936528)
- No head-to-head trials vs enfortumab vedotin completed
- Long-term survival data still maturing (median follow-up ~2-3 years)
- Optimal sequencing with other Nectin-4 targeting agents unknown
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
IV infusion administered over 30-60 minutes. Rapid distribution to Nectin-4-expressing tumors due to small molecular size. Plasma half-life of 3-6 hours.
Weekly dosing at 5 mg/kg RP2D. Initial tumor assessment typically at 8-12 weeks per clinical trial protocols. Early responders may show tumor marker changes.
First radiographic response assessment. In Phase 1/2 trials, responses observed across this timeframe. Disease control rate of 77% (CR + PR + SD).
Median duration of response 11.1 months in responders. Continued weekly dosing until progression or unacceptable toxicity. Some patients achieve durable complete responses.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Zelenectide Pevedotin product quality
Good Signs (6 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Zelenectide Pevedotin with other peptides. Based on published research and mechanistic considerations.
Pembrolizumab
CompatibleCombination studies planned. Checkpoint inhibitors may complement BDC mechanism. Preclinical data suggests enhanced efficacy with PD-1 inhibition.
Sacituzumab-Govitecan
CompatibleDifferent targets (Nectin-4 vs Trop-2) and payloads (MMAE vs SN-38). Sequential use in urothelial cancer may be feasible based on distinct mechanisms.
Enfortumab-Vedotin
CautionBoth target Nectin-4 with MMAE payload. Sequential use may be possible as BT8009 shows activity post-EV (~30-35% ORR). No concurrent use data available.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Zelenectide Pevedotin
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.